Abstract
To describe the rationale for, and the findings of, the Treat-to-Target Trial and to compare its results with those of two subsequent studies based on the same concepts. The 24-hour pattern of hyperglycemia in type 2 diabetes is presented, and its separate components are identified in an attempt to help optimize therapeutic interventions for diabetes. In addition, the treat-to-target concept, including glycemic outcomes and potential adverse effects, is discussed. Using a hemoglobin A1c (A1c) value of 7% as a treatment goal based on evidence from interventional studies and a fasting plasma glucose level of 100 mg/dL as a target for titration of dosage of basal insulin, the Treat-to-Target Trial tested two hypotheses. It confirmed that addition of basal insulin to previously unsuccessful oral therapies can, using a simple algorithm, restore glycemic control to 7% A1c or better in most patients with type 2 diabetes. It also confirmed that a long-acting insulin analogue, glargine, causes less hypoglycemia than human NPH insulin when used in this way. Two subsequent studies using similar treatment algorithms showed comparable ability to improve glycemic control but also demonstrated more frequent unwanted effects of insulin treatme...Continue Reading
References
Feb 26, 1977·Lancet·R R Holman, R C Turner
Jun 1, 1990·Diabetes Care·M C Riddle
Sep 1, 1989·The Journal of Clinical Endocrinology and Metabolism·E T ShapiroK S Polonsky
May 1, 1989·Diabetes·M R TaskinenH Yki-Järvinen
Jan 26, 1985·Lancet·M C Riddle
Jun 1, 1995·Diabetes Care·K CusiJ P Comstock
Sep 1, 1995·Diabetes·K RebrinR N Bergman
Apr 1, 1996·Diabetes·G F LewisA Giacca
Oct 20, 1999·Diabetologia·G B BolliV A Koivisto
Jun 27, 2000·Diabetes Care·M HanefeldC Guitard
Sep 12, 2000·Lancet·G B Bolli, D R Owens
Dec 16, 2000·Diabetes·M LeporeG B Bolli
Oct 4, 2002·The American Journal of Medicine·John E Gerich
Nov 28, 2002·Diabetes Care·Mary F CarrollDavid S Schade
Mar 1, 2003·Diabetes Care·Louis MonnierClaude Colette
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Nov 7, 2003·The Journal of Clinical Endocrinology and Metabolism·Mary F CarrollDavid S Schade
Dec 25, 2003·Diabetes·Mary Courtney MooreAlan D Cherrington
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Dec 24, 2004·Diabetes Care·Floris A van de LaarChris van Weel
Jan 29, 2005·Diabetes Care·Hans U JankaHannele Yki-Järvinen
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group
Jan 29, 2005·Diabetes Care·Antonio CerielloMeng H Tan
Citations
Apr 25, 2012·Diabetologia·S E InzucchiD R Matthews
Apr 17, 2010·Primary Care Diabetes·Luigi MeneghiniMartin J Abrahamson
Feb 19, 2014·Nature Reviews. Endocrinology·Vivian A Fonseca, Michelle A Haggar
Aug 7, 2013·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Pedro Mezquita-RayaUNKNOWN Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition (SEEN)
Aug 25, 2015·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Arumugam KamaladeviKrishnaswamy Balamurugan
Dec 18, 2012·Diabetes, Obesity & Metabolism·S C L GoughM Davies
Oct 15, 2013·Diabetes, Obesity & Metabolism·A J Garber
Sep 22, 2009·The American Journal of Cardiology·George G RhoadsJoanne M Foody
Jul 17, 2008·Diabetes, Obesity & Metabolism·G Dailey
Aug 22, 2018·Diabetes, Obesity & Metabolism·Weiqing WangJun Yang
Apr 20, 2007·The Cochrane Database of Systematic Reviews·K HorvathA Siebenhofer
Apr 21, 2012·Diabetes Care·Silvio E InzucchiUNKNOWN European Association for the Study of Diabetes (EASD)
Jan 1, 2012·Expert Review of Endocrinology & Metabolism·Luigi F Meneghini, Bresta Miranda-Palma
Apr 1, 2017·Expert Opinion on Drug Delivery·Timothy S Bailey, Jenine Y Stone
Jul 1, 2014·Expert Review of Endocrinology & Metabolism·Victoria Stokes, Stephen Cl Gough
May 18, 2013·Hospital Practice·Bernard CharbonnelSylvie Dejager